Shionogi Acquires IntraBio for $2 Billion to Expand Rare Disease Portfolio

Shionogi will pay $2 billion in cash to acquire IntraBio, the companies announced on October 5, 2026. The Japanese pharmaceutical firm will turn the Texas-based biotech into a wholly owned subsidiary of its U.S. Division, which is headquartered in New Jersey.

Strategic rationale

This acquisition expands the rare disease business Shionogi launched last year with its $2.5 billion purchase of global rights to the ALS drug Radicava from Tanabe Pharma. The addition of the commercial-stage drug Aqneursa bolsters Shionogi's portfolio as it sees rare disease treatments playing a larger role in its future. CEO Isao Teshirogi stated that bringing Aqneursa to Shionogi after the Radicava deal will deepen the company's commitment to rare disease communities, expand its capabilities, and strengthen its portfolio for advancing future innovation for patients with significant unmet needs.

About Aqneursa and its approvals

The main asset from IntraBio is the drug levacetylleucine, marketed under the brand name Aqneursa. It emerged from research at the University of Oxford. Aqneursa combats the toxic buildup of lipids in cells and was initially approved by the U.S. FDA in 2024 for treating neurological manifestations of Niemann-Pick disease type C, a condition affecting about one in a million people in the United States. That approval was based on data from a clinical trial where use of the drug was associated with improved patient scores on an evaluation of movement disorders.

Last month, the FDA expanded Aqneursa's label to include ataxia-telangiectasia, making it the first approved therapy for that inherited disorder. The clearance followed data showing a similar benefit in people with that condition.

IntraBio’s background and commercial performance

IntraBio was founded in 2015 with scientific founders from the University of Oxford and the University of Munich. The company discovered and developed small molecules that modulate lysosomal function and intracellular calcium signaling. Initially based in Oxford, U.K., the firm relocated to Austin, Texas, in 2024. IntraBio reported sales of $68 million in 2025. According to Shionogi, Aqneursa generated $67.8 million in revenue in the fiscal year 2025.

Broader pipeline and future outlook

Shionogi highlighted additional early-stage rare neurodegenerative disease programs recently added to its pipeline. The company has set a 2030 target date for achieving its growth goals, which include entering the rare disease business overseas. Aside from Radicava, Shionogi's U.S. Portfolio includes the COVID-19 medicine Xocova and a treatment for complicated urinary tract and hospital acquired respiratory infections. Also, an experimental treatment acquired through a 2020 buyout of Tetra Therapeutics is currently in a Phase 3 trial for the neurological condition Fragile X syndrome.

Shionogi said it will review the transaction’s effects on its financial outlook for the current fiscal year, which ends next March.